APLM
OtherApollomics Inc - Class A
Live · NASDAQ · May 9, Close
What's Moving APLM Today?
No stock-specific AI insight has been generated for APLM yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
APLM News
7 articles- Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business ProgressYahoo Finance·Apr 27, 2026
- Apollomics Inc. Announces $2.0 Million Bridge FinancingYahoo Finance·Apr 1, 2026
- Apollomics Reports First Half 2025 Financial ResultsYahoo Finance·Dec 22, 2025
- Apollomics Announces Settlement of Cayman LitigationYahoo Finance·Nov 19, 2025
- Apollomics Announces Changes to its Board of Directors and Composition of CommitteesYahoo Finance·Nov 18, 2025
- Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing CancellationYahoo Finance·Oct 15, 2025
- Apollomics, Inc. Company Operational Continuity UpdateYahoo Finance·Oct 14, 2025
All 7 articles loaded
Price Data
Fundamentals
Trading
About Apollomics Inc - Class A
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.